VAPO - Vapotherm draws downgrade at William Blair after 2Q results

• Vapotherm, Inc. ( NYSE: VAPO ), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares.
• The analysts led by Margaret Kaczor attribute the revenue miss to pressure on disposables as hospitals destocked the inventory purchased during the Omicron wave.
• However, the team remains optimistic about the benefit Vapotherm ( VAPO ) can count on due to the sizable installed base established during the COVID.
• In addition, they highlight the management's long-term strategy to become a patient management company for complex lung disease.
• However, they downgrade the stock to Market Perform from Outperform, noting the concerns over low liquidity and near-term uncertainty.
• Wall Street has remained bullish on Vapotherm ( VAPO ) stock, with an average rating of Buy from analysts , while Seeking Alpha Author ratings indicated a Hold rating. However, Seeking Alpha's quant system, which consistently beats the market , continued to rate Vapotherm ( VAPO ) a Strong Sell since March.

For further details see: